Boehringer Ingelheim
A privately owned global pharmaceutical company focused on human medicines, animal health and biopharmaceutical research.
Last updated August 31, 2026
AI crawler reads
4requests
1companies- Anthropic4
- Profile
- 2
- Controversies
- 2
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
Boehringer Ingelheim is a German pharmaceutical group headquartered in Ingelheim am Rhein. Founded in 1885 by Albert Boehringer, the company began as a small tartar manufacturer and later developed industrial processes for producing lactic acid and other chemical intermediates. Its early chemical expertise created the technical and financial base for a gradual move into pharmaceutical research and manufacturing. The company remains privately held and is controlled by the Boehringer, Liebrecht and von Baumbach families. This ownership structure distinguishes it from most large multinational drug companies, which are publicly traded or controlled by diversified corporate groups. Private ownership has enabled Boehringer Ingelheim to pursue long-term research, portfolio development and partnerships without the same quarterly-market pressures faced by listed peers, although the company still operates within highly regulated pharmaceutical markets. Its principal businesses are Human Pharma, Animal Health and biopharmaceutical contract development and manufacturing. Human Pharma has concentrated on respiratory diseases, cardiometabolic conditions, immunology, oncology, diseases of the central nervous system and other areas of significant unmet medical need. Important medicines associated with the company include Spiriva for chronic obstructive pulmonary disease, Jardiance for type 2 diabetes and related cardiovascular and renal indications, Ofev for fibrotic lung diseases, Pradaxa for stroke prevention in atrial fibrillation and other thromboembolic indications, and Giotrif/Gilotrif for selected lung cancers. Product availability, commercial rights and indications vary by country and over time. Animal Health is the group’s other major operating pillar. Its portfolio includes medicines, vaccines and parasiticides for companion animals, livestock and other veterinary uses. Products and brands associated with this business include Metacam, Vetmedin, Pexion, NexGard, Purevax and vaccines for dogs, cats and farm animals. The 2016 acquisition of Sanofi’s Merial animal-health business substantially expanded Boehringer Ingelheim’s veterinary scale and helped make the company one of the leading global animal-health groups. The company operates research, development and manufacturing activities across Europe, North America and Asia. Major research locations have included Biberach in Germany, Ridgefield in Connecticut, Vienna, Kobe and other international sites. Boehringer Ingelheim also works with universities, biotechnology companies, public-private research programs and technology companies. Its collaboration with Google Quantum AI, announced in 2021, explored quantum-computing applications for pharmaceutical research, including molecular simulations. Boehringer Ingelheim’s history also includes product-liability litigation, regulatory settlements and manufacturing-quality challenges. The company paid settlements relating to Pradaxa injury claims and alleged off-label marketing, while the closure of its Ben Venue manufacturing plant in Ohio followed serious inspection findings and an unsuccessful effort to restore sustainable production. These events form part of the company’s regulatory and operational history, but do not change its current status as an active international pharmaceutical business.
History
Boehringer Ingelheim traces its origins to 1885, when Albert Boehringer purchased a small tartar factory in Ingelheim am Rhein. The business initially manufactured tartaric acid for food-related applications, including baking powder and carbonated drinks. Experiments in citric-acid production led to an industrial process for lactic acid, which became an important commercial success during the company’s formative years. In 1893, the business adopted the name C. H. Boehringer Sohn in honor of Albert Boehringer’s father. Scientific research became increasingly important in the early twentieth century. In 1917, chemist Heinrich Otto Wieland established a research department at the company. Boehringer Ingelheim expanded beyond its original chemical activities in 1928 through the acquisition of Dr. Karl Thomae, a pharmaceutical company based near Stuttgart. That business was later rebuilt after the Second World War and became an important part of the group’s pharmaceutical manufacturing and research organization. The postwar period brought international expansion and diversification. Boehringer Ingelheim established its Animal Health division in 1955 after acquiring Pfizer’s veterinary program. It expanded into Greece in the 1960s and founded Boehringer Ingelheim Pharmaceuticals in the United States in 1971. Biotechnology capabilities grew through research and manufacturing investments, including the establishment of a biotechnology center in Biberach in 1986. The company also supported the Research Institute of Molecular Pathology in Vienna, which opened in 1988 following a collaboration involving Genentech. In 1998, Boehringer Ingelheim KG and Dr. Karl Thomae GmbH were combined to form Boehringer Ingelheim Pharma KG. During the 2000s and early 2010s, the group pursued acquisitions and licensing transactions in respiratory medicine, oncology, immunology, biotechnology and animal health. It acquired STEAG microParts in 2004, expanded its U.S. veterinary business through assets from Pfizer’s Fort Dodge Animal Health operation in 2009, and acquired Japanese company SSP in 2010. A major strategic turning point came in 2016, when Boehringer Ingelheim and Sanofi agreed to exchange businesses. Boehringer Ingelheim transferred its consumer-health operation and cash, while acquiring Merial, Sanofi’s animal-health division. The transaction transformed the scale of Boehringer Ingelheim’s veterinary business. Some acquired or legacy assets were subsequently divested, including certain animal-health products and a U.S. pet-vaccine operation sold to Elanco. From 2018 onward, the company increased its emphasis on cancer immunotherapy, biological medicines, viral therapies and advanced research partnerships. It announced collaborations with OSE Immunotherapeutics and Topas Therapeutics, acquired ViraTherapeutics, and completed acquisitions involving Amal Therapeutics, Northern Biologics, Labor Dr. Merk & Kollegen, NBE Therapeutics and Abexxa Biologics. In parallel, it expanded animal-health capabilities through the acquisition of Global Stem cell Technology. Boehringer Ingelheim has also faced regulatory and legal challenges. A U.S. settlement in 2012 addressed allegations of off-label promotion, while Pradaxa litigation was resolved through a large settlement in 2014. Its Ben Venue facility in Ohio was voluntarily shut down after serious inspection findings and ultimately closed in 2013. Despite these controversies, the group remains active as a privately owned multinational pharmaceutical company with principal operations in human medicines, animal health and biopharmaceutical research.
- 2021
Quantum-computing research collaboration announced
[1]Boehringer Ingelheim and Google Quantum AI began exploring quantum-computing applications in drug research.
- 2016
Merial acquired through Sanofi asset exchange
[1]The company exchanged its consumer-health business and cash for Sanofi’s Merial animal-health division.
- 1998
Pharmaceutical businesses consolidated
[1]Boehringer Ingelheim KG and Dr. Karl Thomae GmbH were merged into Boehringer Ingelheim Pharma KG.
- 1971
U.S. pharmaceutical subsidiary founded
[1]Boehringer Ingelheim Pharmaceuticals was established in Ridgefield, Connecticut, which became a major North American research location.
- 1955
Animal Health division established
[1]The company entered organized veterinary medicine through the acquisition of Pfizer’s veterinary program.
- 1917
Research department established
[1]Heinrich Otto Wieland established a formal research department within the company.
- 1895
Industrial lactic-acid production
[1]Boehringer Ingelheim began large-scale production of lactic acid after developing a commercially successful process.
- 1886
Tartaric-acid production begins
[1]The factory began producing tartaric acid for food-industry applications.
- 1885
Company founded in Ingelheim
[1]Albert Boehringer acquired a small tartar factory, establishing the business that became Boehringer Ingelheim.
Products and positioning
A research-led, long-term privately owned pharmaceutical group serving human and animal health markets.
Respiratory medicine
Spiriva
A tiotropium-based inhaled medicine used in the management of chronic obstructive pulmonary disease. Spiriva became one of Boehringer Ingelheim’s best-known respiratory brands and represents the company’s longstanding focus on inhaled therapies.
Cardiometabolic medicine
Jardiance
An empagliflozin-based medicine developed with Eli Lilly. It is used in type 2 diabetes and has gained additional cardiovascular and kidney-related indications in different markets.
Respiratory medicine
Ofev
A nintedanib-based treatment used for selected fibrotic lung diseases. The brand reflects Boehringer Ingelheim’s investment in progressive pulmonary fibrosis and other serious respiratory conditions.
Anticoagulant
Pradaxa
A dabigatran-based oral anticoagulant used in indications including prevention of stroke and systemic embolism in appropriate patients with atrial fibrillation, as well as treatment or prevention of venous thromboembolism in specified settings.
Oncology medicine
Giotrif/Gilotrif
An afatinib-based targeted therapy used for selected patients with EGFR-mutated non-small-cell lung cancer. The brand is marketed under different names in different territories.
Animal health
NexGard
Afoxolaner-based parasite-control products for dogs. The NexGard family forms part of Boehringer Ingelheim’s companion-animal portfolio and is used against specified flea and tick infestations.
Animal health
Vetmedin
A pimobendan-based veterinary medicine used in selected canine cardiac conditions. It is one of the company’s established companion-animal therapeutic brands.
Veterinary vaccines
Purevax
A family of feline vaccines designed to help protect cats against specified infectious diseases. It is part of Boehringer Ingelheim’s broader companion-animal vaccine business.
Controversies
2022
Boehringer Ingelheim sues Laurus over Jardiance patent
Boehringer Ingelheim Pharmaceuticals and related entities filed a lawsuit against Laurus Labs and Laurus Generics in Delaware, alleging patent infringement related to a generic version of Jardiance and seeking injunctive relief and monetary damages.
2014
Pradaxa bleeding-injury litigation
The company agreed to a $650 million settlement involving approximately 3,900 claimants in U.S. litigation alleging severe bleeding events associated with Pradaxa.
2012
Off-label promotion settlement
Boehringer Ingelheim paid $95 million to resolve allegations concerning off-label promotion of several medicines and claims involving federal healthcare-program reimbursement.
2011
Ben Venue manufacturing and quality-control problems
U.S. regulatory inspectors reported serious conditions at the company’s Ben Venue facility, including corrosion, mold and an unidentified liquid later described as urine. The plant was voluntarily shut down, partially restarted after substantial investment and ultimately closed in 2013.
1954
Employment of convicted war criminal
Historical accounts state that the company employed Fritz Fischer after his release from prison. Fischer had been convicted at the Nuremberg trials for war crimes and crimes against humanity. The company’s wartime history and involvement in chemical supply are subjects of historical scrutiny.
Brand decisions
2021
Launch quantum-computing research collaborationOtherBackground
Pharmaceutical research involves computationally intensive problems such as molecular dynamics and drug-design simulations.
Action taken
Boehringer Ingelheim established a collaboration with Google Quantum AI and created internal capabilities to examine quantum-computing use cases.
Aftermath
The collaboration positioned the company among pharmaceutical firms investigating emerging computational technologies for research and development.
2017
Increase emphasis on specialty medicines and innovationStrategyBackground
The company’s portfolio increasingly centered on respiratory disease, oncology, immunology, cardiometabolic disease and biotechnology.
Action taken
Boehringer Ingelheim expanded research partnerships, acquisitions and licensing activity in biological therapies, cancer immunotherapy and advanced drug platforms.
Aftermath
The group developed a broader pipeline in targeted medicines, viral therapies, immuno-oncology and biopharmaceutical research.
2016
Exchange consumer health for Merial animal healthM&ABackground
Boehringer Ingelheim sought greater scale in animal health while Sanofi pursued a different portfolio balance.
Action taken
The company transferred its consumer-health division and paid additional cash to Sanofi, receiving Merial in return.
Aftermath
The transaction made animal health a much larger strategic pillar and contributed to Boehringer Ingelheim’s position among the leading global veterinary businesses.
Recent events
- Unconfirmed
Reported
FDA approves Jardiance for adults with heart failure[4]
The FDA approved Boehringer Ingelheim's drug Jardiance, co-developed with Eli Lilly, to mitigate the risk of cardiovascular death and hospitalization for heart failure in adults.
Reported
Boehringer Ingelheim sues Laurus over Jardiance patent[3]
Boehringer Ingelheim Pharmaceuticals and related entities filed a lawsuit against Laurus Labs and Laurus Generics in Delaware, alleging patent infringement related to a generic version of Jardiance and seeking injunctive relief and monetary damages.
- Unconfirmed
Reported
Boehringer Ingelheim acquires Abexxa Biologics[5]
Boehringer Ingelheim acquired Abexxa Biologics. The deal includes an undisclosed upfront payment, milestones and other payments; financial details were not disclosed.
Reported
Boehringer Ingelheim announces acquisition of Abexxa Biologics[6]
Boehringer Ingelheim announced that it had acquired Abexxa Biologics, a biopharmaceutical company focused on immuno-oncology and oncology research. The acquisition gives Boehringer Ingelheim access to Abexxa’s expertise in targeting cancer-specific proteins inside cells.
Reported
ImaginAb and Boehringer Ingelheim sign license and supply agreement[7]
ImaginAb announced that it signed a new multi-year, non-exclusive license agreement with Boehringer Ingelheim. Under the agreement, ImaginAb will supply clinical doses of its 89Zr CD8 ImmunoPET technology for use in clinical development of Boehringer Ingelheim oncology therapeutics in North America and Europe.
Reported
WEHI and Boehringer Ingelheim establish cancer drug research partnership[8]
WEHI and Boehringer Ingelheim established a three-year research collaboration to discover and develop anti-cancer therapeutics using targeted protein degradation.
Reported
Elsevier releases updated DDIRC 2.0 in PharmaPendium[9]
Elsevier, together with pharmaceutical collaborators, further refined and extended its drug-drug interaction risk calculator in PharmaPendium. The DDIRC 2.0 release includes updated visualizations and filters, a more comprehensive dataset, and improved dossier submission support.
Boehringer Ingelheim appoints Vani Manja as India Country Managing Director[10]
Boehringer Ingelheim appointed Vani Manja as Country Managing Director for India, effective January 1, 2021. She also joined the company’s Board.
Reported
Boehringer Ingelheim announces acquisition of Northern Biologics[11]
Boehringer Ingelheim announced its acquisition of Northern Biologics Inc. The seller will retain the Northern Biologics name and continue certain preclinical work on one program, while Boehringer Ingelheim will lead clinical, regulatory and commercial development of the acquired programs.
- Unconfirmed
Reported
Boehringer Ingelheim and Carebox launch MyStudyWindow[12]
Boehringer Ingelheim and Carebox Healthcare Solutions announced the recent launch of MyStudyWindow, a digital platform providing information about Boehringer Ingelheim studies and helping users identify potentially relevant clinical trials.
Sources13 sources
- 1Boehringer Ingelheimen.wikipedia.org
- 2Boehringer Ingelheim official websiteboehringer-ingelheim.com
- 3Boehringer Ingelheim sues Laurus over Jardiance patentlawstreetmedia.com
- 4FDA批准Jardiance用于成人心力衰竭患者finanznachrichten.de
- 5勃林格殷格翰收购 Abexxa Biologicspharmaceutical-business-review.com
- 6勃林格殷格翰宣布收购 Abexxa Biologicsfinanznachrichten.de
- 7ImaginAb 与 Boehringer Ingelheim 签署许可及供应协议prnewswire.com
- 8WEHI与勃林格殷格翰建立癌症药物研究合作news-medical.net
- 9Elsevier在PharmaPendium推出更新版DDIRC 2.0finanznachrichten.de
- 10勃林格殷格翰任命Vani Manja为印度国家董事总经理biospectrumindia.com
- 11勃林格殷格翰宣布收购 Northern Biologicsfinanznachrichten.de
- 12勃林格殷格翰与 Carebox 推出 MyStudyWindowfinanznachrichten.de
- 13Genedata与勃林格殷格翰扩大合作prweb.com
Cite this profile: Cite the canonical profile. /brand-wiki/boehringer-ingelheim · Editorial policy · How profiles are compiled